首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.
【2h】

Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.

机译:羧苄青霉素加头孢唑林联合或不联合美西林作为革兰氏阴性菌引起的菌血症的早期治疗:随机双盲研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mecillinam or a placebo was added to a combination of cefazolin and carbenicillin as an early therapy of septicemia caused by gram-negative organisms in patients with serious underlying diseases, none of whom was neutropenic, however. Patients in whom infection was caused by pathogens against which mecillinam and cefazolin or mecillinam and carbenicillin were synergistic might have responded more often than patients treated with nonsynergistic combinations. However, overall results did not show any benefit from combining mecillinam with cefazolin and carbenicillin. This study suggests that in nonneutropenic patients with septicemia caused by gram-negative organisms, there is no need to intensify antimicrobial therapy beyond a certain point of efficacy. The measurement of the bactericidal activity in the serum of treated patients might serve as guide for adequate therapy.
机译:美西林或安慰剂被添加到头孢唑林和羧苄青霉素的组合中,作为革兰氏阴性菌引起的严重基础疾病患者的败血病的早期治疗,但是这些患者均不是中性粒细胞减少的。感染是由与美西林和头孢唑啉或美西林和羧苄青霉素协同作用的病原体引起的患者比非协同组合治疗的患者更容易发生反应。但是,总体结果并未显示美西林与头孢唑林和羧苄青霉素合用没有任何益处。这项研究表明,在由革兰氏阴性生物引起的败血症的非中性粒细胞减少患者中,无需加强抗菌治疗,而不必超过特定的疗效。所治疗患者血清中杀菌活性的测定可作为适当治疗的指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号